Advertisement

Carcinoid Heart Disease

  • Anita Nguyen
  • Hartzell V. SchaffEmail author
  • Heidi M. Connolly
Chapter
  • 8 Downloads

Abstract

Carcinoid is a rare neuroendocrine tumor that typically originates in the gastrointestinal tract and can result in a constellation of symptoms, mediated by vasoactive substances, referred to as carcinoid syndrome. Carcinoid valve and heart disease is characterized by the plaque-like, endocardial fibrous tissue deposits, primarily affecting the right heart endocardium and valves, which result as a consequence of the disease process. Potential mechanisms for the carcinoid valve disease include the complex role of excess serotonin and its interaction with serotonin receptors and transporters. Carcinoid valve and heart disease is a frequent occurrence in patients with carcinoid syndrome and is accountable for substantial morbidity and mortality. Cardiac surgery remains the most effective treatment option for carcinoid valve disease and a multidisciplinary approach at an experienced center is recommended for patients with metastatic carcinoid and carcinoid heart disease. This chapter provides an overview of the pathophysiology, clinical presentation and treatment of carcinoid heart disease as well as early and late outcomes of valve replacement in this condition.

Keywords

Carcinoid heart disease Carcinoid syndrome Pulmonary valve replacement Right-sided heart failure Serotonin Tricuspid valve replacement 

Notes

Acknowledgements

This work was supported by the Paul and Ruby Tsai Family.

Disclosures: None.

References

  1. 1.
    Davar J, Connolly HM, Caplin ME, et al. Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors: an expert statement. J Am Coll Cardiol. 2017;69:1288–304.CrossRefGoogle Scholar
  2. 2.
    Pellikka PA, Tajik AJ, Khandheria BK, et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation. 1993;87:1188–96.CrossRefGoogle Scholar
  3. 3.
    Lillegard JB, Fisher JE, Mckenzie TJ, et al. Hepatic resection for the carcinoid syndrome in patients with severe carcinoid heart disease: does valve replacement permit safe hepatic resection? J Am Coll Surg. 2011;213:130–6.CrossRefGoogle Scholar
  4. 4.
    van Vilsteren FGI, Baskin-Bey ES, Nagorney DM, et al. Liver transplantation for gastroenteropancreatic neuroendocrine cancers: defining selection criteria to improve survival. Liver Transpl. 2006;12:448–56.CrossRefGoogle Scholar
  5. 5.
    Chaowalit N, Connolly HM, Schaff HV, Webb MJ, Pellikka PA. Carcinoid heart disease associated with primary ovarian carcinoid tumor. Am J Cardiol. 2004;93:1314–5.CrossRefGoogle Scholar
  6. 6.
    Ahlman H. Serotonin and carcinoid tumors. J Cardiovasc Pharmacol. 1985;7(Suppl 7):S79–85.CrossRefGoogle Scholar
  7. 7.
    Connolly HM, Schaff HV, Mullany CJ, Rubin J, Abel MD, Pellikka PA. Surgical management of left-sided carcinoid heart disease. Circulation. 2001;104:I36–40.CrossRefGoogle Scholar
  8. 8.
    Simula DV, Edwards WD, Tazelaar HD, Connolly HM, Schaff HV. Surgical pathology of carcinoid heart disease: a study of 139 valves from 75 patients spanning 20 years. Mayo Clin Proc. 2002;77:139–47.CrossRefGoogle Scholar
  9. 9.
    Rajamannan NM, Caplice N, Anthikad F, Sebo TJ, Orszulak TA, Edwards WD, et al. Cell proliferation in carcinoid valve disease: a mechanism for serotonin effects. J Heart Valve Dis. 2001;10:827–31.PubMedGoogle Scholar
  10. 10.
    Gustafsson BI, Tømmerås K, Nordrum I, Loennechen JP, Brunsvik A, Solligård E, et al. Long-term serotonin administration induces heart valve disease in rats. Circulation. 2005;111:1517–22.CrossRefGoogle Scholar
  11. 11.
    Connolly HM, Nishimura RA, Smith HC, Pellikka PA, Mullany CJ, Kvols LK. Outcome of cardiac surgery for carcinoid heart disease. J Am Coll Cardiol. 1995;25:410–6.CrossRefGoogle Scholar
  12. 12.
    Møller JE, Pellikka PA, Bernheim AM, Schaff HV, Rubin J, Connolly HM. Prognosis of carcinoid heart disease: analysis of 200 cases over two decades. Circulation. 2005;112:3320–7.CrossRefGoogle Scholar
  13. 13.
    Connolly HM, Schaff HV, Abel MD, Rubin J, Askew JW, Li Z, et al. Early and late outcomes of surgical treatment in carcinoid heart disease. J Am Coll Cardiol. 2015;66:2189–96.CrossRefGoogle Scholar
  14. 14.
    Castillo J, Silvay G, Weiner M. Anesthetic management of patients with carcinoid syndrome and carcinoid heart disease: the Mount Sinai algorithm. J Cardiothorac Vasc Anesth. 2018;32:1023–31.CrossRefGoogle Scholar
  15. 15.
    Connolly HM, Schaff HV, Mullany CJ, Abel MD, Pellikka PA. Carcinoid heart disease: impact of pulmonary valve replacement in right ventricular function and remodeling. Circulation. 2002;106:I51–6.PubMedGoogle Scholar
  16. 16.
    Egbe A, Pislaru SV, Ali MA, Khan AR, Boler AN, Schaff HV, et al. Early prosthetic valve dysfunction due to bioprosthetic valve thrombosis: the role of echocardiography. JACC Cardiovasc Imaging. 2018;11:951–8.CrossRefGoogle Scholar
  17. 17.
    Egbe AC, Connolly HM, Pellikka PA, Schaff HV, Hanna R, Maleszewski JJ, et al. Outcomes of warfarin therapy for bioprosthetic valve thrombosis of surgically implanted valves: a prospective study. JACC Cardiovasc Interv. 2017;10:379–87.CrossRefGoogle Scholar
  18. 18.
    Hassan SA, Banchs J, Iliescu C, Dasari A, Lopez-Mattei J, Yusuf SW. Carcinoid heart disease. Heart. 2017;103:1488–95.CrossRefGoogle Scholar
  19. 19.
    De Jesus T, Allen SL, Ryu JH, et al. Carcinoid heart disease in patients with bronchopulmonary carcinoid. J Thorac Oncol. 2018;13:1602–5.CrossRefGoogle Scholar
  20. 20.
    Arghami A, Connolly HM, Abel MD, Schaff HV. Quadruple valve replacement in patients with carcinoid heart disease. J Thorac Cardiovasc Surg. 2010;140:1432–4.CrossRefGoogle Scholar
  21. 21.
    Robiolio PA, Rigolin VH, Harrison JK, Lowe JE, Moore JO, Bashore TM, et al. Predictors of outcome of tricuspid valve replacement in carcinoid heart disease. Am J Cardiol. 1995;75:485–8.CrossRefGoogle Scholar
  22. 22.
    Castillo JG, Milla F, Adams DH. Surgical management of carcinoid heart valve disease. Semin Thorac Cardiovasc Surg. 2012;24:254–60.CrossRefGoogle Scholar
  23. 23.
    Bhattacharyya S, Raja SG, Toumpanakis C, Caplin ME, Dreyfus GD, Davar J. Outcomes, risks and complications of cardiac surgery for carcinoid heart disease. Eur J Cardiothorac Surg. 2011;40:168–72.CrossRefGoogle Scholar
  24. 24.
    Mokhles P, van Herwerden LA, de Jong PL, et al. Carcinoid heart disease: outcomes after surgical valve replacement. Eur J Cardiothorac Surg. 2012;41:1278–83.CrossRefGoogle Scholar
  25. 25.
    Rankin JS, He X, O’Brien SM, et al. The Society of Thoracic Surgeons risk model for operative mortality after multiple valve surgery. Ann Thorac Surg. 2013;95:1484–90.CrossRefGoogle Scholar
  26. 26.
    Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Orthod. 2008;26:3063–72.Google Scholar
  27. 27.
    Nguyen A, Schaff HV, Abel MD, Luis SA, Lahr BD, Halfdanarson TR, et al. Improving outcome of valve replacement for carcinoid heart disease. J Thorac Cardiovasc Surg. 2019;158(1):99–107.e2.CrossRefGoogle Scholar
  28. 28.
    Weingarten TN, Abel MD, Connolly HM, Schroeder DR, Schaff HV. Intraoperative management of patients with carcinoid heart disease having valvular surgery: a review of one hundred consecutive cases. Anesth Analg. 2007;105:1192–9.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Anita Nguyen
    • 1
  • Hartzell V. Schaff
    • 1
    Email author
  • Heidi M. Connolly
    • 2
  1. 1.Department of Cardiovascular SurgeryMayo ClinicRochesterUSA
  2. 2.Department of Cardiovascular MedicineMayo ClinicRochesterUSA

Personalised recommendations